Emergent BioSolutions

EBS · NYSE · United States

Share price · EBS

$5.50+0.84 (+18.03%) 3M

close as of 2026-11-18 · 24h delayed · vol 817K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when EBS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-5.6%
  2. 5 Oct 2026+14.4%
  3. 7 Aug 2026-8.9%

    Nothing announced by EBS that day or the session before.

  4. 6 Aug 2026-29.6%
  5. 14 Jul 2026-6.4%

    Nothing announced by EBS that day or the session before.

  6. 25 Jun 2026-5.3%

    Nothing announced by EBS that day or the session before.

  7. 2 Mar 2026+10.3%

    Nothing announced by EBS that day or the session before.

  8. 27 Feb 2026-26.6%

Share of unusual movement by asset

For each asset, the share of EBS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Naloxone (Narcan) (Narcan)
events and moves
1shown from 8 days
ACAM2000
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—47%
Sessions with no dated event—53%

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Orthopoxvirus immunity (live vaccinia vaccine)Vaccine
Poxvirus Infections
Smallpox and Mpox
Approved
B. anthracis protective antigenVaccine
Anthrax
Approved
Opioid receptorSmall molecule
Opioid Overdose

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$110M$9.4M$177M$33M$100M operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$9.2M$141M$180M$56M operating cash flowreport ↗
2026-Q1—$11M$162M—-$34M operating cash flowreport ↗
2025-Q3—$14M$249M—-$2.3M operating cash flowreport ↗
2025-Q2—$13M$271M$12M$106M operating cash flowreport ↗
2025-Q1—$15M$153M—-$11M operating cash flowreport ↗
2024-Q3$294M$14M$156M—$154M operating cash flowreport ↗
2024-Q2$255M$33M$71M$283M$48M operating cash flowreport ↗
2024-Q1$300M$15M$79M—-$63M operating cash flowreport ↗
2023-Q3$271M$15M$88M$263M$60M operating cash flowreport ↗
2023-Q2$338M$26M$89M$261M-$114M operating cash flowreport ↗
2023-Q1$165M$41M$430M$183M-$184M operating cash flowreport ↗
2022-Q4$330M—$643M$67M$93M operating cash flowreport ↗
2022-Q3$240M$39M$241M$76M-$74M operating cash flowreport ↗
2022-Q2$243M$50M$358M$56M-$16M operating cash flowreport ↗
2022-Q1$308M$46M$436M$3.7M-$37M operating cash flowreport ↗
2021-Q4$733M—$576M—$329M operating cash flowreport ↗
2021-Q3$329M$50M$404M$33M$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$743M$53M$209M—$171M operating cash flowreport ↗

For fiscal 2025, Emergent BioSolutions reported revenue of $742.9M, down 28.8% YoY from $1,043.6M, with R&D spend of $53.2M, down 24.8% YoY. Cash and equivalents totaled $209.1M, and the company reported net income of $52.6M; quarterly net burn was not disclosed.

During the year, management highlighted completion of the Baltimore-Bayview facility sale to Syngene for approximately $36.5M, acquisition of exclusive U.S. and Canadian commercial rights to KLOXXADO from Hikma, and receipt of all $80.0M in Bavarian Nordic milestones. The company also secured multiple U.S. government contract actions across ACAM2000, CYFENDUS, CNJ-016, BAT, TEMBEXA, and BioThrax, plus a BARDA option for Ebanga, while deciding at year-end to deprioritize several early-stage candidates, including EBS-MARV, EBS-SUDV, Pan-Ebola mAbs, and WEVEE-VLP.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.0B$71M$106M$48M$59M operating cash flowreport ↗
2023-FY$1.0B$111M$112M$190M-$206M operating cash flowreport ↗
2022-FY$1.1B$193M$643M$56M-$34M operating cash flowreport ↗
2021-FY$1.8B$234M$576M—$321M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($986K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-07DeGolyer Donald W · directorOpen-market sale17,800$7.09$126KForm 4
2026-10-01Williams Paul Anthony · SVP, Products BusinessOpen-market sale3,000$6.53$20KForm 4
2026-07-01Williams Paul Anthony · SVP, Products BusinessOpen-market sale3,000$8.40$25KForm 4
2026-06-08Hartzel William · SVP, BioservicesTax withholding1,741$8.00$14KForm 4
2026-06-08Glessner Coleen · EVP, Quality & Ethics, and CPLTax withholding2,018$8.00$16KForm 4
2026-06-08LINDAHL RICHARD S · EVP, Chief Financial OfficerTax withholding3,964$8.00$32KForm 4
2026-06-08Williams Paul Anthony · SVP, Products BusinessTax withholding694$8.00$6KForm 4
2026-05-01Zoon Kathryn C · directorOpen-market sale16,145$8.36$135KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 187 reporting institutions held 42.6M shares ($331.8M, 82.9% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.4,341,462$36.0M
2STATE STREET CORP2,849,701$23.7M
3DIMENSIONAL FUND ADVISORS LP2,757,158$22.9M
4AMERICAN CENTURY COMPANIES INC2,425,722$20.1M
5VANGUARD CAPITAL MANAGEMENT LLC2,257,995$18.7M
6CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,506,075$12.5M
7GEODE CAPITAL MANAGEMENT, LLC1,272,909$10.6M
8PALISADE CAPITAL MANAGEMENT, LP1,201,323$10.0M
9VANGUARD PORTFOLIO MANAGEMENT LLC1,117,278$9.3M
10OAK HILL ADVISORS LP1,113,338$9.2M
11D. E. Shaw & Co., Inc.1,003,912$8.3M
12AQR CAPITAL MANAGEMENT LLC989,677$8.2M
13GOLDMAN SACHS GROUP INC811,560$6.7M
14Prescott Group Capital Management, L.L.C.772,771$6.4M
15MORGAN STANLEY744,536$6.2M